{'fraction_non_alphanumeric': 0.014598540145985401, 'fraction_numerical': 0.0009124087591240876, 'mean_word_length': 5.341040462427745, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of Boswellia‐based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma

The complication of breast conserving approach after radiotheraphy is radiodermitis. It causes damage to the woman and in particular in older breast cancer patients. The best treatment could be a medicament applied topically during radiotherapy to prevent and to treat toxicity without negative side effects. The recent report by the Togni’s group (1) have shown that a Boswelliabased cream reduces use of topical corticosteroids and is able to reduce the grade of erythema and the skin superficial symptoms, being well tolerated by the patients. In this report, lesions have been evaluated by a new measurement mode of the damage erythematosus of radiation. The authors used a computerized evaluation of erythematous mammary area with a photographic support. This method, reproducible and standardized, can be easily introduced in daily medical practice to also reduce the toxicity from radiation. This may be a great opportunity to continue to reduce damage from chemotherapeutic treatments.